Emergent BioSolutions (EBS) Stock Forecast, Price Target & Predictions
EBS Stock Forecast
Emergent BioSolutions stock forecast is as follows: an average price target of $51.50 (represents a 401.46% upside from EBS’s last price of $10.27) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
EBS Price Target
The average price target for Emergent BioSolutions (EBS) is $51.50 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $65.00 to $38.00. This represents a potential 401.46% upside from EBS's last price of $10.27.
EBS Analyst Ratings
According to 4 Wall Street analysts, Emergent BioSolutions's rating consensus is 'Buy'. The analyst rating breakdown for EBS stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Emergent BioSolutions Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 04, 2022 | Wells Fargo | $38.00 | $33.06 | 14.94% | 270.01% | |
| Apr 29, 2022 | Chardan Capital | $65.00 | $33.98 | 91.29% | 532.91% |
The latest Emergent BioSolutions stock forecast, released on May 04, 2022 by Wells Fargo company, set a price target of $38.00, which represents a 14.94% increase from the stock price at the time of the forecast ($33.06), and a 270.01% increase from EBS last price ($10.27).
Emergent BioSolutions Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $10.27 | $10.27 | $10.27 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Emergent BioSolutions stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Emergent BioSolutions's last price of $10.27. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 30, 2024 | H.C. Wainwright | Buy | Initialise | |
| Aug 22, 2024 | Rodman & Renshaw | Buy | Initialise | |
| Aug 16, 2024 | Benchmark Co. | Underperform | Underperform | Hold |
| Aug 16, 2024 | Benchmark | Buy | Buy | Hold |
| Jun 24, 2024 | Benchmark Co. | Underperform | Underperform | Hold |
| Jun 20, 2024 | Benchmark | Buy | Buy | Hold |
| Mar 07, 2024 | Benchmark | Positive | Buy | Upgrade |
| Apr 10, 2023 | Benchmark | Hold | Positive | Upgrade |
| Nov 10, 2022 | Benchmark | Hold | Downgrade | |
| Apr 29, 2022 | Chardan Capital | Buy | Buy | Hold |
Emergent BioSolutions's last stock rating was published by H.C. Wainwright on Dec 30, 2024. The company Initialise its EBS rating from "null" to "Buy".
Emergent BioSolutions Financial Forecast
Emergent BioSolutions Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $270.50M | $337.90M | $165.10M | $330.70M | $240.00M | $242.70M | $307.50M | $723.20M | $329.00M | $397.50M | $343.00M | $583.00M | $385.20M | $394.70M | $192.50M | $360.30M | $311.80M | $243.20M | $190.60M | $117.81M | $116.86M |
| Avg Forecast | $274.00M | $304.00M | $309.00M | $279.00M | $249.50M | $290.33M | $190.00M | $220.25M | $293.41M | $237.43M | $216.17M | $159.73M | $297.18M | $268.30M | $270.94M | $283.57M | $669.04M | $486.84M | $398.93M | $358.41M | $573.21M | $437.89M | $294.72M | $198.89M | $357.41M | $289.27M | $212.06M | $201.16M | $863.87M | $120.93M |
| High Forecast | $292.95M | $325.03M | $330.37M | $315.10M | $264.70M | $302.50M | $203.14M | $235.48M | $313.70M | $237.43M | $231.12M | $170.78M | $302.34M | $268.30M | $270.94M | $283.57M | $669.04M | $486.84M | $398.93M | $358.41M | $573.21M | $437.89M | $294.72M | $198.89M | $357.41M | $289.27M | $212.06M | $201.16M | $1.04B | $145.12M |
| Low Forecast | $255.05M | $282.97M | $287.63M | $242.90M | $234.30M | $278.17M | $176.86M | $205.02M | $273.12M | $237.43M | $201.22M | $148.69M | $292.02M | $268.30M | $270.94M | $283.57M | $669.04M | $486.84M | $398.93M | $358.41M | $573.21M | $437.89M | $294.72M | $198.89M | $357.41M | $289.27M | $212.06M | $201.16M | $691.09M | $96.74M |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 12 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.14% | 1.56% | 1.03% | 1.11% | 0.89% | 0.90% | 1.08% | 1.08% | 0.68% | 1.00% | 0.96% | 1.02% | 0.88% | 1.34% | 0.97% | 1.01% | 1.08% | 1.15% | 0.95% | 0.14% | 0.97% |
Emergent BioSolutions's average Quarter revenue forecast for Dec 23 based on 2 analysts is $293.41M, with a low forecast of $273.12M, and a high forecast of $313.70M. EBS's average Quarter revenue forecast represents a 8.47% increase compared to the company's last Quarter revenue of $270.50M (Sep 23).
Emergent BioSolutions EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 12 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-11.00M | $-292.90M | $-108.60M | $-16.10M | $-23.10M | $-30.50M | $35.30M | $305.70M | $-4.40M | $49.00M | $122.40M | $290.40M | $91.40M | $155.70M | $15.50M | $108.50M | $96.90M | $22.90M | $-1.60M | $3.18M | $25.75M |
| Avg Forecast | $16.61M | $18.43M | $18.74M | $16.92M | $15.13M | $17.60M | $11.52M | $34.76M | $17.79M | $14.40M | $13.11M | $27.48M | $18.02M | $41.62M | $42.03M | $21.72M | $103.79M | $75.53M | $61.89M | $77.59M | $88.93M | $67.93M | $45.72M | $15.50M | $55.45M | $44.88M | $32.90M | $-4.96M | $6.12M | $26.61M |
| High Forecast | $17.76M | $19.71M | $20.03M | $19.10M | $16.05M | $18.34M | $12.32M | $41.71M | $19.02M | $14.40M | $14.01M | $32.98M | $18.33M | $41.62M | $42.03M | $26.07M | $103.79M | $75.53M | $61.89M | $93.11M | $88.93M | $67.93M | $45.72M | $18.60M | $55.45M | $44.88M | $32.90M | $-3.97M | $7.35M | $31.93M |
| Low Forecast | $15.46M | $17.16M | $17.44M | $14.73M | $14.21M | $16.87M | $10.72M | $27.81M | $16.56M | $14.40M | $12.20M | $21.98M | $17.71M | $41.62M | $42.03M | $17.38M | $103.79M | $75.53M | $61.89M | $62.07M | $88.93M | $67.93M | $45.72M | $12.40M | $55.45M | $44.88M | $32.90M | $-5.95M | $4.90M | $21.29M |
| Surprise % | - | - | - | - | - | - | - | - | - | -0.76% | -22.35% | -3.95% | -0.89% | -0.55% | -0.73% | 1.63% | 2.95% | -0.06% | 0.79% | 1.58% | 3.27% | 1.35% | 3.41% | 1.00% | 1.96% | 2.16% | 0.70% | 0.32% | 0.52% | 0.97% |
1 analysts predict EBS's average Quarter EBITDA for Jun 22 to be $42.03M, with a high of $42.03M and a low of $42.03M. This is 19.08% upper than Emergent BioSolutions's previous annual EBITDA (Mar 22) of $35.30M.
Emergent BioSolutions Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 12 |
| Net Income | - | - | - | - | - | - | - | - | - | $-265.90M | $-261.30M | $-183.00M | $-88.00M | $-75.70M | $-56.40M | $-3.70M | $189.30M | $-32.70M | $4.60M | $69.70M | $185.40M | $39.50M | $92.70M | $-12.50M | $46.90M | $43.20M | $-9.50M | $-26.00M | $-4.91M | $10.48M |
| Avg Forecast | $-7.23M | $62.83M | $-5.56M | $63.38M | $-27.99M | $5.75M | $-63.11M | $-3.64M | $-10.56M | $-12.42M | $-35.95M | $-2.88M | $197.01M | $-3.24M | $19.99M | $-2.28M | $222.65M | $123.52M | $76.27M | $44.18M | $167.64M | $111.25M | $35.94M | $-12.50M | $91.22M | $47.11M | $8.79M | $-80.60M | $-9.44M | $10.83M |
| High Forecast | $-6.58M | $68.48M | $-5.06M | $69.08M | $-25.47M | $6.26M | $-57.43M | $-2.91M | $-9.61M | $-11.30M | $-32.72M | $-2.30M | $236.42M | $-3.24M | $19.99M | $-1.82M | $222.65M | $123.52M | $76.27M | $53.02M | $167.64M | $111.25M | $35.94M | $-10.00M | $91.22M | $47.11M | $8.79M | $-64.48M | $-7.55M | $13.00M |
| Low Forecast | $-7.88M | $57.18M | $-6.06M | $57.69M | $-30.50M | $5.23M | $-68.78M | $-4.37M | $-11.51M | $-13.53M | $-39.19M | $-3.46M | $157.61M | $-3.24M | $19.99M | $-2.73M | $222.65M | $123.52M | $76.27M | $35.35M | $167.64M | $111.25M | $35.94M | $-15.00M | $91.22M | $47.11M | $8.79M | $-96.72M | $-11.32M | $8.67M |
| Surprise % | - | - | - | - | - | - | - | - | - | 21.41% | 7.27% | 63.53% | -0.45% | 23.34% | -2.82% | 1.63% | 0.85% | -0.26% | 0.06% | 1.58% | 1.11% | 0.36% | 2.58% | 1.00% | 0.51% | 0.92% | -1.08% | 0.32% | 0.52% | 0.97% |
Emergent BioSolutions's average Quarter net income forecast for Mar 22 is $-2.28M, with a range of $-2.73M to $-1.82M. EBS's average Quarter net income forecast represents a -101.20% decrease compared to the company's last Quarter net income of $189.30M (Dec 21).
Emergent BioSolutions SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 12 |
| SG&A | - | - | - | - | - | - | - | - | - | $86.00M | $91.40M | $100.50M | $94.20M | $80.20M | $81.10M | $84.80M | $94.20M | $82.10M | $91.20M | $80.90M | $82.10M | $75.50M | $76.00M | $69.70M | $72.20M | $65.00M | $70.80M | $65.40M | $40.20M | $35.15M |
| Avg Forecast | $70.76M | $78.51M | $79.80M | $72.06M | $64.44M | $74.98M | $49.07M | $83.51M | $75.78M | $61.32M | $55.83M | $66.01M | $98.04M | $68.69M | $69.37M | $52.18M | $171.30M | $124.65M | $102.14M | $51.28M | $146.76M | $112.11M | $75.46M | $69.70M | $91.51M | $74.06M | $54.29M | $51.50M | $77.30M | $36.32M |
| High Forecast | $75.66M | $83.94M | $85.32M | $81.38M | $68.36M | $78.12M | $52.46M | $100.21M | $81.02M | $61.32M | $59.69M | $79.22M | $117.65M | $68.69M | $69.37M | $62.62M | $171.30M | $124.65M | $102.14M | $61.54M | $146.76M | $112.11M | $75.46M | $83.64M | $91.51M | $74.06M | $54.29M | $51.50M | $92.76M | $43.59M |
| Low Forecast | $65.87M | $73.08M | $74.28M | $62.73M | $60.51M | $71.84M | $45.68M | $66.81M | $70.54M | $61.32M | $51.97M | $52.81M | $78.43M | $68.69M | $69.37M | $41.75M | $171.30M | $124.65M | $102.14M | $41.03M | $146.76M | $112.11M | $75.46M | $55.76M | $91.51M | $74.06M | $54.29M | $51.50M | $61.84M | $29.06M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.40% | 1.64% | 1.52% | 0.96% | 1.17% | 1.17% | 1.63% | 0.55% | 0.66% | 0.89% | 1.58% | 0.56% | 0.67% | 1.01% | 1.00% | 0.79% | 0.88% | 1.30% | 1.27% | 0.52% | 0.97% |
Emergent BioSolutions's average Quarter SG&A projection for Dec 23 is $75.78M, based on 2 Wall Street analysts, with a range of $70.54M to $81.02M. The forecast indicates a -11.89% fall compared to EBS last annual SG&A of $86.00M (Sep 23).
Emergent BioSolutions EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 12 |
| EPS | - | - | - | - | - | - | - | - | - | $-5.13 | $-5.15 | $-3.65 | $-1.76 | $-1.52 | $-1.13 | $-0.07 | $3.54 | $-0.61 | $0.09 | $1.31 | $3.51 | $0.75 | $1.76 | $-0.24 | $0.91 | $0.84 | $-0.18 | $-0.51 | $-0.10 | $0.26 |
| Avg Forecast | $-0.13 | $1.13 | $-0.10 | $1.14 | $-0.50 | $0.10 | $-1.14 | $-0.98 | $-0.19 | $-0.22 | $-0.65 | $-1.29 | $0.04 | $-0.06 | $0.38 | $0.13 | $4.23 | $2.35 | $1.45 | $1.15 | $3.19 | $2.12 | $0.68 | $0.01 | $1.73 | $0.90 | $0.17 | $0.09 | $0.42 | $0.31 |
| High Forecast | $-0.12 | $1.23 | $-0.09 | $1.24 | $-0.46 | $0.11 | $-1.03 | $-0.89 | $-0.17 | $-0.20 | $-0.59 | $-1.18 | $0.04 | $-0.06 | $0.38 | $0.13 | $4.23 | $2.35 | $1.45 | $1.15 | $3.19 | $2.12 | $0.68 | $0.01 | $1.73 | $0.90 | $0.17 | $0.09 | $0.51 | $0.37 |
| Low Forecast | $-0.14 | $1.03 | $-0.11 | $1.04 | $-0.55 | $0.09 | $-1.24 | $-1.07 | $-0.21 | $-0.24 | $-0.70 | $-1.41 | $0.04 | $-0.06 | $0.38 | $0.13 | $4.23 | $2.35 | $1.45 | $1.15 | $3.19 | $2.12 | $0.68 | $0.01 | $1.73 | $0.90 | $0.17 | $0.09 | $0.34 | $0.25 |
| Surprise % | - | - | - | - | - | - | - | - | - | 22.97% | 7.96% | 2.82% | -40.00% | 24.65% | -2.97% | -0.58% | 0.84% | -0.26% | 0.06% | 1.14% | 1.10% | 0.35% | 2.58% | -24.00% | 0.52% | 0.94% | -1.08% | -5.41% | -0.24% | 0.84% |
According to 1 Wall Street analysts, Emergent BioSolutions's projected average Quarter EPS for Mar 22 is $0.13, with a low estimate of $0.13 and a high estimate of $0.13. This represents a -96.47% decrease compared to EBS previous annual EPS of $3.54 (Dec 21).
Emergent BioSolutions Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EBS | Emergent BioSolutions | $10.32 | $51.50 | 399.03% | Buy |
| COLL | Collegium Pharmaceutical | $29.51 | $42.33 | 43.44% | Buy |
| ZTS | Zoetis | $163.31 | $221.00 | 35.33% | Buy |
| ALKS | Alkermes | $29.04 | $37.50 | 29.13% | Hold |
| NBIX | Neurocrine Biosciences | $138.10 | $156.14 | 13.06% | Buy |
| ITCI | Intra-Cellular Therapies | $83.72 | $94.25 | 12.58% | Buy |
| PBH | Prestige Consumer Healthcare | $76.88 | $86.00 | 11.86% | Buy |
| BHC | Bausch Health Companies | $7.80 | $8.33 | 6.79% | Hold |
| LFCR | Lifecore Biomedical | $7.62 | $6.50 | -14.70% | Buy |